DR. STEVEN JEFFREY HAGER D.O. NPI 1326087917

NPI Details

DR. Steven Jeffrey Hager, D.O. is a hematology and oncology internal medicine in Fresno, CA with 42 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Steven Jeffrey Hager, D.O. NPI is 1326087917. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: NEW YORK COLLEGE OF OSTEO MEDICINE OF NEW YORK INSTITUTE OF TECHNOLOGY
Graduation Year:1984

The provider's business location address is:

7130 N MILLBROOK AVE
FRESNO, CA
ZIP 93720-347
Phone: (559) 326-1222
Fax: (559) 326-1230

The NPI 1326087917 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, azacitidine, 1 mg (HCPCS:J9025)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, testosterone cypionate, 1 mg (HCPCS:J1071)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg (HCPCS:Q5118)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, atezolizumab, 10 mg (HCPCS:J9022)
• Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml (HCPCS:Q9967)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, granisetron, extended-release, 0.1 mg (HCPCS:J1627)
• Injection, rituximab-arrx, biosimilar, (riabni), 10 mg (HCPCS:Q5123)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, pegfilgrastim-apgf, biosimilar, (nyvepria), 0.5 mg (HCPCS:Q5122)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Flow cytometry technique for dna or cell analysis, each additional marker (HCPCS:88185)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Unclassified drugs (HCPCS:J3490)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Blood test, clotting time (HCPCS:85610)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Ferritin (blood protein) level (HCPCS:82728)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• Electrophoresis, laboratory testing technique (HCPCS:82664)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Red blood count, automated test (HCPCS:85045)
• Urinalysis, manual test (HCPCS:81002)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 125 (HCPCS:86304)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Injection, alteplase recombinant, 1 mg (HCPCS:J2997)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Haptoglobin (serum protein) level (HCPCS:83010)
• Ct scan of chest with contrast (HCPCS:71260)
• Telephone medical discussion with physician, 5-10 minutes (HCPCS:99441)
• Injection, hydrocortisone sodium succinate, up to 100 mg (HCPCS:J1720)
• Ct scan of abdomen and pelvis with contrast (HCPCS:74177)
• New patient office or other outpatient visit, 30-44 minutes (HCPCS:99203)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Testosterone (hormone) level, total (HCPCS:84403)
• Application of on-body injector for under skin injection (HCPCS:96377)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Telephone medical discussion with physician, 11-20 minutes (HCPCS:99442)
• Red blood cell sedimentation rate, to detect inflammation, non-automated (HCPCS:85651)
• Vitamin d-3 level (HCPCS:82306)
• Administration of influenza virus vaccine (HCPCS:G0008)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Declotting of central venous tube (HCPCS:36593)
• Flow cytometry technique for dna or cell analysis, first marker (HCPCS:88184)
• Influenza vaccine split virus, preservative free (HCPCS:90662)
• Unclassified biologics (HCPCS:J3590)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Magnesium level (HCPCS:83735)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)

The enumeration date for this NPI number is 6/6/2006 and was last updated on 1/27/2020.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.